Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CHIMERIX INC (CMRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Investor presentation, Quarterly results
Docs: "Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update – Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries&#59; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –",
"Chimerix Corporate Presentation August 3, 2023 2 Forward-Looking Statements This"
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Investor presentation, Quarterly results
Docs: "Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update – Continued Execution and Progress Towards Commercial Approval of Dordaviprone with Global Launch of Phase 3 ACTION Study –",
"2 Forward-Looking Statements This"
01/12/2023 8-K Investor presentation
Docs: "Annual J.P. Morgan Healthcare Conference January 12, 2023"
12/09/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/31/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
08/08/2022 8-K Quarterly results
08/01/2022 8-K Other Events  Interactive Data
06/28/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chimerix, Inc.Officer Severance Benefit Plan"
04/13/2022 8-K Regulation FD Disclosure  Interactive Data
03/01/2022 8-K Quarterly results
01/31/2022 8-K Quarterly results
12/23/2021 8-K Other Events  Interactive Data
11/22/2021 8-K Investor presentation
11/04/2021 8-K Quarterly results
Docs: "Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update – Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –",
"Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma – Blinded Independent Central Review of ONC201 Cohort Reported 20.0% Objective Response Rate by RANO-HGG Criteria –"
08/05/2021 8-K Quarterly results
Docs: "Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update – Received U.S. Food and Drug Administration Approval for TEMBEXA® for the Treatment of Smallpox –"
06/25/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "11,765,000 Shares CHIMERIX, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT",
"2505 Meridian Parkway, Suite 100"
01/19/2021 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Cohn Reznick LLP, independent registered public accounting firm",
"Audited financial statements of Oncoceutics as of and for the years ended December 31, 2019 and 2018, together with the notes thereto and the auditors' report thereon",
"Unaudited interim financial statements of Oncoceutics as of September 30, 2020 and for the nine months ended September 30, 2020 and 2019",
"Unaudited pro forma consolidated combined balance sheet for the Company and Oncoceutics as of September 30, 2020 and unaudited pro forma consolidated combined statements of operations for the Company and Oncoceutics for the year ended December 31, 2019 and for the nine months ended September 30, 2020"
01/13/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy